Increased coagulation in childhood obesity

Pediatric Hematology and Oncology

Volumn 29, Issue 8, 2012, Pages 721-727

  Bilge, Yildiz Dallar ^a   Alioglu, Bulent ^a   Şimşek, Enver ^a   Tapci, Ayse Esra ^a   Özen, Çinar ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Anticoagulant factors; Antithrombin; Factor IX; Factor VIII; Fibrinolysis; Obesity; Procoagulant factors; Von Willebrand factor

Indexed keywords

EID: 84867942233     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2012.729649     Document Type: Article

References (39)

1. Cinaz P. Obezite. Guncel C ocuk Sagligi. 2008;1(3):289-303.
2. WHO. Obesity: Preventing andmanaging the global epidemic. Report of aWHOconsultation. World Health Organ Tech Rep Ser. 2000:894(i-xii):1-253.
3. Ogden C, Carroll M, Curtin L, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295:1549-1555.
4. Barlow SE, Dietz WH. Obesity evaluation and treatment: Expert committee recommendations.The maternal and child health bureau, health resources and services administration and the department of health and human services. Pediatrics. 1998;102:E29.
5. Weiss R, Dziura J, Burgert TS, et al.Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004;350:2362-2374.
6. Saraç F, SaydamG, T̈uz̈un M, et al. Obezitede trombosit fonksiyonlari. Turkish J Endocrin Metabol. 2003;SUPPL 2:69-72.
7. Anfossi G, Russo I, Trovati M. Platelet dysfunction in central obesity. Nutr Metab Cardiovasc Dis. 2009;19:440-449.
8. Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obes Rev. 2002;3: 85-101.
9. Nagai N,HoylaertsMF,CleurenAC, et al. Obesitypromotes injury induced femoral artery thrombosis in mice. Thromb Res. 2008;122:549-555.
10. Rosito GA, D'Agostino RB, Massaro J, et al. Association between obesity and a prothrombotic state: The framingham offspring study. Thromb Haemost. 2004;91:683-689.
11. Darvall KAL, Sam RC, Silverman SH, et al. Obesity and thrombosis. Eur J Vasc Endovasc Surg. 2007;33:223-233.
12. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: A meta-Analysis and review of the literature. Ann Int Med. 1993;118:956-963.
13. Wilhelmsen L, Sv̈ardsudd K, Korsan-Bengtsen K, et al. Fibrinogen as a risk factor for stroke andmyocardial infarction.N Engl J Med. 1984;311:501-505.
14. Heinrich J, Balleisen L, Schulte H, et al. Fibrinogen and factor VII in the prediction of coronary risk. Results fromthe PROCAM study in healthy men. Arterioscler Thromb. 1994;14:54-59.
15. Kannel WB, D'Agostino RB, Belanger AJ. Update on fibrinogen as a cardiovascular risk factor. Ann Epidemiol. 1992;2:457-466.
16. Rillaerts E,VanGaal L,Xiang DZ, et al.Blood viscosity in human obesity: Relation to glucose tolerance and insulin status. Int J Obes. 1989;13:7139-7745.
17. Fanari P, Somazzi R, Nasrawi F, et al. Haemorheological changes in obese adolescents after shorttermdiet. Int J Obes. 1993;17:487-494.
18. Avellone G, Di Garbo V, Cordova R, et al. Evaluation of cardiovascular risk factors in overweight and obese subjects. Int Angiol. 1994;13:25-29.
19. Licata G, Scaglione R, Avellone G, et al. Hemostatic function in young subjects with central obesity: Relationship with left ventricular function. Metabolism. 1995;44:1417-1421.
20. Moerloose P, Boehlen F, Neerman-Arbez M. Fibrinogen and the risk of thrombosis. Semin Thromb Hemost. 2010;36:7-17.
21. Fritsch P, Kleber M, Rosenkranz A, et al. Haemostatic alterations in overweight children: Associations between metabolic syndrome, trombin generation, and fibrinogen levels. Atherosclerosis. 2010;212:650-655.
22. Balleisen L, Bailey J, Epping PH, et al. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population. I. Baseline data on the relation to age, gender, body weight, smoking, alcohol, pill-using, and menopause. Thromb Haemost. 1985;54:475-479.
23. Dahlgren E, Janson PO, Johansson S, et al.Hemostatic and metabolic variables in women with polycystic ovary syndrome. Fertil Steril. 1994;61:455-460.
24. Cigolini M, TargherG, BergamoAndreis IA, et al. Visceral fat accumulation and its relation to plasma hemostatic factors in healthymen. Arterioscler Thromb Vasc Biol. 1996;16:368-374.
25. Licata G, Scaglione R, Avellone G, et al. Hemostatic function in young subjects with central obesity: Relationship with left ventricular function. Metabolism. 1995;44:1417-1421.
26. Folsom AR, Qamhieh HT, Wing RR, et al. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler Thromb. 1993;13:162-169.
27. Frankel DS, Meigs JB, Massaro JM, et al. Von Willebrand factor, type 2 diabetes mellitus, and risk of cardiovascular disease: The framingham offspring study. Circulation. 2008;118:2533-2539.
28. Renn'e T, Nieswandt B, Gailani D.The intrinsic pathway of coagulation is essential for thrombus stability in mice. Blood Cells Mol Dis. 2006;36:148-151.
29. Tucker EI, Marzec UM, White TC, et al. Prevention of vascular graft occlusion and thrombusassociated thrombin generation by inhibition of factor XI. Blood. 2009;113:936-944.
30. Bereczky Z, Katona E, Muszbek L. Fibrin stabilization (factor XIII), fibrin structure and thrombosis. Pathophysiol Haemost Thromb. 2003;33:430-437.
31. Gui T, Reheman A, Funkhouser WK, et al. In vivo response to vascular injury in the absence of factor IX: Examination in factor IX knockoutmice. Thromb Res. 2007;121:225-234.
32. Meade TW,Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park heart study. Lancet. 1986;2:533-537.
33. van-Hylckama-Vlieg A, van-der-Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. Blood. 2000;95:3678-3682.
34. Weltermann A, Eichinger S, Bialonczyk C, et al. The risk of recurrent venous thromboembolism among patients with high factor IX levels. J Thromb Haemost. 2003;1:28-32.
35. Conlan MG, Folsom AR, Finch A, et al. Associations of factor VIII and von Willebrand factor with age, race, gender, and risk factors for atherosclerosis.Theatherosclerosis risk incommunities (ARIC) study. Thromb Haemost, 1993;70:380-385.
36. Kaye M, Pietil̈ainen KH, Kotronen A, et al. Obesity-related derangements of coagulation and fibrinolysis: A study of obesity-discordant monozygotic twin pairs. Obesity. 2012;20:88-94.
37. Blann AD, Bushell D, Davies A, et al. vonWillebrand factor, the endothelium and obesity. Int J Obes. 1993;17:723-725.
38. Batist G, Bothe A, Bern M, et al. Lowantithrombin III in morbid obesity: Return to normalwith weight reduction. J Parent Enteral Nutr. 1983;7:447-449.
39. Rudnicka AR, Rumley A, Lowe GDO, StrachanDP. Diurnal, seasonal, and blood-processing patterns in levels of circulating fibrinogen, fibrin d-dimer, C-reactive protein, tissue plasminogen activator, and vonWillebrand factor in a 45-year-old population. Circulation. 2007;115:996-1003.